KMTS Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $24.6 million, a 63% increase year-over-year.
Gross Margin: 52.6%, up from 43.4% in the prior year, marking the ninth consecutive quarter of sequential gross margin expansion.
Operating Expenses: $47.7 million, including $1.5 million in nonrecurring costs related to professional fees.
Net Loss: $34.2 million, compared to a loss of $21.8 million in the prior year.
Adjusted EBITDA Loss: $21.2 million, up from $16.3 million year-over-year.
Cash Position: $291 million as of January 31, 2026.

2. Strategic Updates and Business Highlights

Prescription Growth: Over 5,400 prescriptions for the Assure system were written, reflecting a 58% year-over-year increase.
Market Expansion: The wearable cardioverter defibrillator (WCD) market is estimated to grow in the low- to mid-teens percentage range, with KMTS capturing a significant share.
FDA Approval: A new algorithm update for the Assure system was approved, aimed at reducing false alarms and inappropriate shocks.
Partnerships: A strategic collaboration with BioBeat Technologies was announced to integrate blood pressure monitoring into the Assure WCD offering.
Sales Force Expansion: The company is on track to increase sales territories from 100 to 130 by the end of the fiscal year.

3. Forward Guidance and Outlook

Fiscal Year 2026 Revenue Guidance: Increased to $93 million, representing a 55% growth compared to fiscal year 2025, up from previous guidance of $91 million.
Gross Margin Target: Management remains confident in achieving gross margins of over 70% in the coming years.

4. Bad News, Challenges, or Points of Concern

Net Loss: The increase in net loss may raise concerns among investors regarding profitability.
Conversion Rate: Although improved to 46%, there was a slight dip compared to the previous quarters, attributed to seasonal factors and deductible resets in January.
Competitive Landscape: While KMTS is gaining market share, the presence of established competitors like ZOLL poses ongoing challenges. The impact of ZOLL's new product launch remains uncertain.
Operational Challenges: The company noted that the holiday season and the January insurance plan changes create variability in performance.

5. Notable Q&A Insights

Market Dynamics: Management indicated that approximately 70-75% of prescription growth is from current market share shifts rather than new prescribers, suggesting a focus on existing relationships.
Sales Force Strategy: The company is evaluating the potential for faster territory expansion but emphasizes the importance of maintaining service levels and effective execution.
Guidelines Influence: Future market growth may depend on updates to clinical guidelines, which KMTS is actively pursuing through research like the ACE PAS study.
Cash Burn: The cash burn rate is expected to remain in the mid-$20 million range, with ongoing investments in CapEx to support growth.

In conclusion, KMTS reported strong financial performance in Q3 2026, driven by significant revenue growth and margin expansion. Strategic initiatives, including market expansion and product innovation, position the company well for future growth, although challenges related to competition and profitability remain.

KMTS — KESTRA MEDICAL TECHNOLOGIES, LTD.